Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. Issue 2 (February 2022)

• Record Type: Journal Article
• Authors: Sharp, Tyler M; Anderson, Kathryn B; Katzelnick, Leah C; Clapham, Hannah; Johansson, Michael A; Morrison, Amy C; Harris, Eva; Paz-Bailey, Gabriela; Waterman, Stephen H
• Is Part Of: Lancet infectious diseases. Volume 22:Issue 2(2022)
• Page Start: e42
• Page End: e51
• Publication Date: 2022-02
• Subjects: Communicable diseases -- Periodicals; Infection -- Periodicals; Communicable Diseases -- Periodicals; Infection -- Periodicals; Maladies infectieuses -- Périodiques; Infection -- Périodiques; Communicable diseases; Infection; Periodicals; 616.905
• DOI: 10.1016/S1473-3099(20)30871-9
• Languages: English
• ISSNs: 1473-3099

Abstract

Summary: The most severe consequences of dengue virus infection include shock, haemorrhage, and major organ failure; however, the frequency of these manifestations varies, and the relative contribution of pre-existing anti-dengue virus antibodies, virus characteristics, and host factors (including age and comorbidities) are not well understood. Reliable characterisation of the epidemiology of severe dengue first depends on the use of consistent definitions of disease severity. As vaccine trials have shown, severe dengue is a crucial interventional endpoint, yet the infrequency of its occurrence necessitates the inclusion of thousands of study participants to appropriately compare its frequency among participants who have and have not been vaccinated. Hospital admission is frequently used as a proxy for severe dengue; however, lack of specificity and variability in clinical practices limit the reliability of this approach. Although previous infection with a dengue virus is the best characterised risk factor for developing severe dengue, the influence of the timing between dengue virus infections and the sequence of dengue virus infections on disease severity is only beginning to be elucidated. To improve our understanding of the diverse factors that shape the clinical spectrum of disease resulting from dengue virus infection, prospective, community-based and clinic-based immunological, virological, genetic, and clinical studies across a range of ages and geographical regions are needed.